It has been proposed that oncogenic KRAS might promote tumor progression by limiting the efficacy of RAS/RAF/MEK/ERK1/2 signaling, whereas KRAS—responsive tissues exhibit a full activated signaling pathway, and trigger potent antitumor responses [31]. The gene discussed is MAPK3; the disease is neoplasm.